Wednesday, 23 September 2020

BioIVT Announces the Launch of its Next-generation Sequencing Service

17 December 2019 | News

Comprehensive service includes project design, specimen selection, library preparation, sequencing and bioinformatics support

image courtesy: Rapidmicrobiology

image courtesy: Rapidmicrobiology

BioIVT, a leading provider of research models and services for drug and diagnostic development, on 16 Dec 2019, launched its Next-generation Sequencing (NGS) Service, which combines the company’s expertise in human tissue procurement, specimen selection, sample preparation and project management with its in-house NGS capabilities. BioIVT now offers both standard and custom NGS services, including sample extraction, library preparation, sequencing and bioinformatics.

“We are excited to launch our NGS Service to support researchers investigating the human genome to determine the mutations contributing to specific diseases. We are proud to play our part in utilizing this powerful technology to make these important mutations annotated specimens more accessible to the medical research community,” said BioIVT Chief Executive Officer Jeffrey Gatz.

“Our new NGS Service brings together expertise from across BioIVT, including biospecimen procurement, project design, project management, library prep, sequencing and data analysis. This service also builds upon our acquisition of Asterand Biosciences with our clients having immediate access to hundreds of thousands of banked specimens. We are also constantly increasing our bank through our clinical network with samples procured following industry best practices and meeting our ASTERAND® human tissue standards,” said Mr Gatz.

“In keeping with BioIVT’s high-quality standards, we also ensure that every one of our tissue blocks is reviewed by a board-certified pathologist before it is included in an NGS study. This process ensures that every block features the required tissue. We also supply all our specimens with pertinent clinical data and full regulatory approval,” added Shannon Richey, BioIVT Vice President and General Manager, Detroit Operations.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account